Key Takeaways
- Revenue recovery underway, agro leads: Sales improved both YoY and QoQ, driven by a revival in agrochemical volumes and the ramp-up of a new high-value AI molecule, after a subdued first half.
- FY26 growth guided at 25-30%+: Management expects a return to historical growth rates, fueled by LOI commercialization, new molecule launches, and a sharp rise in contributions from Japan and the U.S.
- Working capital is the main drag: Elevated inventory, particularly from past agro buildup, keeps working capital intensity high; management targets a gradual easing as revenue scales and customer reciprocity kicks in.
- New chemistries open adjacent TAMs: An LOI with Elementium for lithium-ion battery electrolytes and a U.S. defense/aerospace contract signal a diversification beyond the core agro-pharma-polymer mix.
- What to watch next quarter: The pace of agro inventory liquidation, the conversion of the Elementium LOI into a firm take-or-pay contract, and whether the guided H2-heavy revenue skew materializes on schedule.
Demand Environment & Segment Recovery
- Agrochemicals turning the corner: The segment, a major drag earlier in FY25, showed signs of revival with volume offtake returning for old molecules and a new high-value AI molecule ramping up. This AI molecule carries triple-digit dollar pricing per kg and targets a 2,800 MT market, with the customer aiming for 5-10% share.
- Pharma and Polymer support the base: These segments contributed to the quarter's improved performance, with 15 new pharma molecules and over 5 performance chemical molecules launched over the last 18 months.
- Geographic mix set to shift: Japan is expected to cross 20% of sales in FY26 on the back of a recently signed LOI and new customer additions. The U.S. opportunity is expected to begin contributing meaningfully and cross 10% of sales in the same period.
- Customer destocking cycle largely complete: Large MNC customers have finished the supply chain and working capital rationalization undertaken over the last 18-24 months, removing a headwind to offtake as business growth resumes.
Anand Desai: "As business growth resumes, customers shall be able to reciprocate by supporting us in optimizing our working capital cycle going forward."
Revenue Growth & LOI Commercialization
- The 25-30% growth call: Management expects a return to historical growth rates from FY26 onwards, underpinned by the commercialization of the majority of balance LOIs and contracts beyond the INR3,100 crores already commercialized.
- H2-heavy phasing: Revenue is expected to be split with 55-60% falling in H2 FY26, driven by the timing of product ramp-ups.
- Revenue potential from current assets: The existing gross block can support INR3,000-3,500 crores of revenue from the current product portfolio, excluding battery chemicals which may require additional capex.
- LOI ramp-up trajectory: LOIs will take time to commercialize and ramp; the INR200 crores from 2022 LOIs will scale going forward, adding to the base.
- The AI molecule's longevity: The new high-value agro AI product is expected to be a long-term molecule lasting at least 5-7 years and growing from there.
Vishal Thakkar: "We should be coming back to our historical growth rates, which have been in the range of 25% to 30% plus. And I think we should be able to continue to see that kind of a growth from '26 onwards."
New Business Development
- Elementium (battery chemicals): An LOI was signed with the MIT-backed company for high-end fluorinated electrolytes for lithium-ion batteries. Anupam will be the primary supplier, leveraging its Tanfac acquisition for a strong competitive edge. Commercialization is expected in 2026, with Elementium looking at 10x higher volumes post-2026, which will require future capacity addition.
- U.S. defense and aerospace entry: A contract and LOI were signed with a U.S.-based company for a high-performance specialty chemical used in critical power applications across defense, electronics, and aerospace.
- Capex cycle nearing completion: Nearly INR670 crores of planned capex is complete. Two manufacturing facilities are already commercialized, and one new facility is ready for commercialization in the upcoming quarter.
- No immediate capex for Elementium: The first 1,000 tons of demand expected in 2026 can be serviced from current capacities. Additional capex will be considered only when a take-or-pay contract is in place.
Vishal Thakkar: "With Elementium, we are the primary supplier for them for this product. And again, this is a product from Tanfac and the acquisition of Tanfac as well. So we believe that we have a very strong edge on this product."
Margins & Mix
- Margins held consistent: Q4 margins reflected a focus on operational efficiency and a favorable product mix, with no significant raw material price volatility to pass through.
- FY26 margin guidance steady: Management expects margins to remain in the historical range of 26-28%, as Pharma and Polymer margins tend to offset each other, and newer products carry a similar margin profile.
- Segment mix target for FY26: Pharma is expected at 20-25% of revenue, Performance Chemicals at 25%+, Personal Care at 8-10%, with the balance in Agro. Lost agro volume is expected to return reasonably.
- Pass-through protection intact: The company retains pass-through clauses with customers for raw material price changes, a mechanism that worked during prior periods of high price volatility.
Vishal Thakkar: "The margins will be quite similar if you really see... the current margins, which you look at, has also been in the similar range, and we expect that the newer products should also give us a similar kind of a margin range, 26% to 28%, which historically we've been guiding."
Balance Sheet & Working Capital
- Working capital remains the pinch point: Elevated working capital intensity, a challenge stemming from the recent sales slowdown, is a key focus area. Inventory buildup from the 2023 agro cycle, when revenue was growing at a 25-30% CAGR with ~70% from agro, has not yet been fully liquidated.
- Inventory composition: A large part of the elevated inventory is agro-related, though management did not confirm a precise split. Pharma and Polymer inventory buildup is tied to campaign production for 15+ new molecules and is expected to normalize as volumes ramp per product.
- Receivables and payables target: Management anticipates a gradual easing of working capital intensity in FY26, with both inventory levels and receivables expected to reduce meaningfully. The target is 200-odd days, plus or minus 20 days, by FY27.
- Debt reduction path: Debt levels are expected to decline, with approximately INR185 crores of long-term debt to be settled through warrant conversion proceeds in FY26. Management expects long-term debt to be practically zero after this conversion.
- New contract working capital: Net working capital for new contracts is expected to be in the 150-180 day range, structurally lower than the current elevated levels.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Return to historical growth rates of 25% to 30%+ | FY26 onwards |
| Japan revenue share | Cross 20% of sales | FY26 |
| U.S. revenue share | Begin contributing meaningfully, cross 10% of sales | FY26 |
| LOI commercialization | Majority of balance LOIs beyond the INR3,100 crores already done | FY26 |
| EBITDA margin | 26% to 28% range | FY26 |
| Long-term debt | Reduced to practically zero via warrant conversion | FY26 |
| Working capital days | Target of ~200 days (±20 days) | FY27 |
| Elementium commercialization | First volumes for lithium-ion battery electrolytes | 2026 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹506 cr, +22% YoY and +31% QoQ |
| Full-year consolidated revenue | ₹1,448 cr, -4% YoY |
| Operating revenue (FY25) | ₹1,437 cr, -2.6% YoY |
| EBITDA (incl. other income) | ₹150 cr, +43% YoY; margin of 30% |
| Full-year EBITDA (incl. other income) | ₹412 cr, +0.4% YoY; margin of 29% |
| Profit after tax | ₹63 cr, +56% YoY |
| Full-year profit after tax | ₹160 cr, vs ₹167 cr in FY24 |
| Pharma segment revenue growth | +41% YoY in Q4; +92% YoY in FY25, reaching 21.9% of sales |
| Japan revenue contribution | 17% of sales, expected to exceed 20% in FY26 |
| US revenue contribution expectation | Over 10% of sales in FY26 |
| Order book | ₹14,646 cr, spread over 4–10 years; ₹3,100 cr commercialized, contributing over 20% of FY25 revenue |
| Capex completed | ~₹670 cr as of March 31, 2025; two facilities commercialized, one ready for commercialization |
| Long-term debt to be settled via warrants | ~₹185 cr expected in FY26 |
| Molecules launched in FY25 | 9 total: 5 in Pharma, 3 in agro, 1 in Polymer |
| Top 10 customer concentration | 71% of total revenue |
| Life science-related specialty chemicals share | 84.4% of Q4 revenue; 86.7% of FY25 revenue |
| Revenue growth guidance | 25% to 30%+ from FY26 onwards, returning to historical rates |
| EBITDA margin guidance | 26% to 28% for newer products |
| Net working capital days target | 200 days ±20 by FY27; 150–180 days for incremental revenue |
| Operating cash flow (H2 FY25) | ~₹140 cr |
| Short-term debt | ~₹1,100 cr |